Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-101 inhaled imatinib dose-ranging and confirmatory study in pulmonary arterial hypertension
NL-OMON59506Phase 3Completed
- Sponsor
- Aerovate Therapeutics
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Primary endpoints: Placebo-corrected change from baseline in pulmonary vascular resistance and Placebo-corrected change from baseline in 6-minute walk distance. Started May 2023; status: completed.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON59506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59506.